Aconabolics is a cutting-edge brand that specializes in the synthesis of stable, isotopically labeled organic acids, ketoacids, and amino acids. Our research mission focuses on providing products and services for diagnostics, pharmaceutical research, and metabolic analysis. With our proprietary reaction pathways, we are able to generate known and non-fermentable metabolites, including isotopic and structural isomers of biochemical intermediates and analogs.

Our groundbreaking technology, known as metabolic flux analysis, enables rapid diagnoses of conditions such as cancer and bacterial infections. We have developed synthetic techniques that produce the necessary chemical reagents, specifically 13C-labelled metabolites that are vital for this technology. These molecules are highly specialized and challenging to produce, but our decade of research experience and substantial funding have allowed us to develop the necessary technology to replicate these intermediates without the need for costly enzymes or fermentation.

By synthesizing 13C-labeled metabolites in high purity and at a low cost, we aim to expand access to these agents and fuel significant growth in both research and diagnostic applications using stable isotopes. Our technology is based on a proprietary series of synthetic protocols that replicate the citric acid cycle, the most important biological pathway in life. These protocols produce no toxic waste and can be carried out in water without organic solvents, making them environmentally friendly.

At Aconabolics, our mission is to lower the cost and increase the accessibility of 13C-labeled metabolites, which are currently being evaluated in clinical trials. We also develop new reagents that allow the visualization of alternative metabolic pathways in various disease states, including cardiomyopathies and traumatic brain injuries. We actively seek partnerships with academic, industrial, and healthcare institutions that are at the forefront of cancer research.

Together, we can expand the technology for the diagnosis of rare cancers and metabolic disorders, ultimately advancing the field of biotechnology. With our expertise, we produce 13C-labeled metabolites in yields and purities that surpass current industry standards, making us a trusted choice for researchers and healthcare professionals alike. Stay tuned for the latest news from Aconabolics, including our recent achievements such as receiving the InnoVision Small Enterprise Award and publishing our TCA Cycle Analog in Nature Chemistry.

Join us on this scientific journey as we strive to make breakthrough discoveries and revolutionize the field of metabolic analysis